title: Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison.
abstract: BACKGROUND
  Treatment strategies that abolish abnormal reflux could prevent long-term complications of gastro-oesophageal reflux disease.
  
  
  OBJECTIVE
  To compare the efficacy of laparoscopic fundoplication and lansoprazole in abolishing abnormal reflux in patients with gastro-oesophageal reflux disease.
  
  
  METHODS
  Study population comprised 130 patients referred for possible antireflux surgery and with heartburn as the dominant symptom.
  
  
  METHODS
  After oesophageal manometric and pH-metric evaluation and detailed information 55 patients asked to undergo laparoscopic antireflux surgery while 75 chose a medical treatment regimen based on lansoprazole. Treatment efficacy was assessed by ambulatory oesophageal pH-monitoring.
  
  
  RESULTS
  All 55 patients who underwent fundoplication became free of heartburn: oesophageal pH-monitoring gave normal results in 85%. In patients treated with lansoprazole, at individualized daily dosages titrated to abolish both heartburn and abnormal acid reflux, normal pH-metric results were obtained in 96% of cases (p<0.05 vs surgically treated patients).
  
  
  CONCLUSIONS
  Lansoprazole at individualized dosages was significantly more effective than laparoscopic fundoplication, in the short-term, in abolishing abnormal reflux in gastro-oesophageal reflux disease patients.
authors.affiliation: Department of Internal Medicine and Gastroenterology, S. Agostino Hospital, Modena, Italy. marziofrazzoni@hotmail.com
authors.forename: M
authors.initials: M
authors.lastname: Frazzoni
authors.forename: A
authors.initials: A
authors.lastname: Grisendi
authors.forename: A
authors.initials: A
authors.lastname: Lanzani
authors.forename: G
authors.initials: G
authors.lastname: Melotti
authors.forename: E
authors.initials: E
authors.lastname: De Micheli
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D018662:Fundoplication / Q000379:methods; D005764:Gastroesophageal Reflux / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery*; D006356:Heartburn / Q000209:etiology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D064747:Lansoprazole; D010535:Laparoscopy; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D054328:Proton Pump Inhibitors; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D009853:Omeprazole